Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

Decade Growing in Plain Sight: Detection of an Invasive Melanoma Within a Long-Standing Pigmented Lesion

Freeman M, Gates G, Ahronowitz I. Decade Growing in Plain Sight: Detection of an Invasive Melanoma Within a Long-Standing Pigmented Lesion. Cureus. 2026 Oct 10;18(10):e117734.[...]

Ethical Considerations of Verbal Versus Written Consent for Minor Dermatologic Procedures

Moon JY, Zhou AE, Soriano T, Davis J, Kim J, Grant-Kels JM. Ethical Considerations of Verbal Versus Written Consent for Minor Dermatologic Procedures. J Am[...]

Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy

Zimmerman MP, Huang AY, Cox EK, Al Abosy R, Chong WL, Bastian AG, Vietor K, Choutri YA, Collier JL, Zhabotynsky V, Wang H, Fung M,[...]